诺雷德联合瑞宁得治疗绝经前复发转移性乳腺癌的临床研究  

ZoladexTm+ arimidexTm in the treatment of premenopausal patients with advanced breast cancer

作　　者：张志强[1] 江泽飞[1] 宋三泰[1] 王涛[1] 申戈[1] 于静新[1] 张少华[1] 闫敏[1] 

机构地区：[1]军事医学科学院307医院乳腺内科,北京100039

出　　处：《癌症进展》2004年第2期127-130,共4页Oncology Progress

摘　　要：目的 研究诺雷德联合瑞宁得治疗绝经前晚期乳腺癌的临床疗效和不良反应。方法 22例绝经前晚期乳腺癌患者应用诺雷德3.6mg,每28天注射一次;瑞宁得1 mg,每日1次,连续口服4周为1周期。9例患者于治疗前1天、治疗后第4天、7天、10天、1个月、2个月分别检测血中雌二醇(E2),黄体生成素(LH)及卵泡刺激素(FSH)水平,所有患者按期评价疗效和不良反应。结果 部分缓解(PR)5例,有效率为22.7％;临床获益(CB=CR+PR+SD≥6月)13例,占59.1％。6例患者在第4-7天时E2有一过性升高,但不影响疗效。结论 诺雷德联合瑞宁得对绝经前晚期乳腺癌疗效肯定,不良反应轻,是乳腺癌内分泌治疗中一种有效的联合方案。To study the clinical effects and side-effects of zoladexTm + arimidexTm in the treatment of premenopausal patients with advanced breast cancer. Methods 22 premenopausal patients with advanced breast cancer were given zoladex 3.6mg daily depot injection every 28 days and arimidex 1mg once daily (po), for four weeks as a circle. Serum levels of E2, LH and FSH were detected in 9 patients on one day before and days 4, 7, 10, 28 and 56 after the treatment. At the same time, clinical effects and side-effect were evaluated in all treated patients. Results There were 5 cases partial response (22.7%), and 13 cases got clinical benefit (CR + PR + SD≥6months) ( 59.1%) . There is a flash rise of serum E2 in six patients in 4-7days since treatment. Anyway this alternation of E2 did not affect the clinical outcome. Conclusion Zoladex combined with arimidex is an effective and low side-effect method in the treatment of premenopausal patients with advanced breast cancer, and this combination also is an effective combined regimen in endocrine therapy of breast cancer.

关 键 词：晚期乳腺癌 内分泌治疗 诺雷德 瑞宁得 

分 类 号：R737.9[医药卫生—肿瘤] R730.54[医药卫生—临床医学]